Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 15th total of 8,400 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average trading volume of 16,800 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its stake in Daxor Co. (NASDAQ:DXR) by 34.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Price Performance

DXR traded up $0.41 during trading on Monday, reaching $8.50. 1,102 shares of the company’s stock were exchanged, compared to its average volume of 5,653. Daxor has a fifty-two week low of $7.19 and a fifty-two week high of $10.02. The company’s fifty day moving average price is $8.56 and its 200-day moving average price is $8.80.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.